Transparency Market Research announces the publication of a new research report on the global CINV existing and pipeline drugs market. Chemotherapy induced nausea and vomiting (CINV) drugs refer to medication or treatment that is offered to cancer patients who experience nausea and vomiting due to chemotherapy. According to the research report published by Transparency Market Research, the global CINV existing and pipeline drugs market is expected to reach US$1.88 billion in 2020 from US$1.28 billion, growing at a CAGR of 5.7% from 2014 to 2020.The report, titled “CINV Existing and Pipeline Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020”, gives a clear understanding of the strengths, weaknesses, opportunities, and threats faced by this market with a SWOT analysis.
Get the Full Report at:
Nausea and vomiting is the most commonly experienced side effect of chemotherapy. Over the years, a range of drugs and medical treatments have been devised to address this issue. However, it continues to be a big battle for both patients and oncologists, thus making it a main reason for the expected growth of the global CINV drugs existing and pipeline market in the coming few years.
The global CINV drugs existing and pipeline market is segmented on the basis of drugs and geography. The drugs making a wave in this market are Akynzeo (netupitant-palonosetron), Emend (aprepitant), Aloxi (palonosetron), Zofran Generic (ondansetron), Kytril Generic (granisetron), SUSTOL (extended release granisetron injection), and Rolapitant. Out of these, the commonly used drugs to control CINV are Zofran (ondansetron), Aloxi (palonosetron), Emend (aprepitant), and Kytril (granisetron). It was only in October 2014 that the U.S. FDA approved Akynzeo for prevention of CINV. This oral dosage drug will give the patients two antiemetics in a single intake, thereby offering them greater relief. Two major CINV drugs, rolapitant and SUSTOL (APF-530), are under the registration phase or phase III and are likely to be introduced in the market in the coming future.
Geographically, the global CINV existing and pipeline drugs market is segmented into Asia Pacific, North America, Europe, and Rest of the World. In 2013, North America accounted for 45% of the revenue generated in the global CINV existing and pipeline drugs market. This region is expected to continue its dominance to emerge as a leading player by 2020. North America will grow at a CAGR of 7% in the forecast period, followed by Europe. Asia Pacific, on the other hand, will grow at a steady pace due to its steadily growing population and increasing number of cancer patients.
Get Free Sample Report Copy at :
The important players leading the global CINV existing and pipeline drugs market are Helsinn Holding S.A., GlaxoSmithKline plc, Merck & Co., Inc. Heron Therapeutics, Inc., and Tesaro, Inc. The research report gives a complete clarity of the financial status of these companies, their competitive marketing strategies, and their plans for investments in the coming years.
Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.
TMR’s data repository is continuously updated and revised by a team of research experts so that it always reflects the latest trends and information. With extensive research and analysis capabilities, Transparency Market Research employs rigorous primary and secondary research techniques to develop distinctive data sets and research material for business reports.
Mr. Nachiket Ghumare
90 State Street, Suite 700
Albany, NY 12207
USA - Canada Toll Free: 866-552-3453